28412023|t|Precise prediction of activators for the human constitutive androstane receptor using structure -based three-dimensional quantitative structure-activity relationship methods
28412023|a|The constitutive androstane receptor (CAR, NR1I3) regulates the expression of numerous drug-metabolizing enzymes and transporters. The upregulation of various enzymes, including CYP2B6, by CAR activators is a critical problem leading to clinically severe drug-drug interactions (DDIs). To date, however, few effective computational approaches for identifying CAR activators exist. In this study, we aimed to develop three-dimensional quantitative structure-activity relationship (3D-QSAR) models to predict the CAR activating potency of compounds emerging in the drug-discovery process. Models were constructed using comparative molecular field analysis (CoMFA) based on the molecular alignments of ligands binding to CAR, which were obtained from ensemble ligand-docking using 28 compounds as a training set. The CoMFA model, modified by adding a lipophilic parameter with calculated logD7.4 (S+logD7.4), demonstrated statistically good predictive ability (r(2) = 0.99, q(2) = 0.74). We also confirmed the excellent predictability of the 3D-QSAR model for CAR activation (r(2)pred = 0.71) using seven compounds as a test set for external validation. Collectively, our results indicate that the 3D-QSAR model developed in this study provides precise prediction of CAR activating potency and, thus, should be useful for selecting drug candidates with minimized DDI risk related to enzyme-induction in the early drug-discovery stage.
28412023	8	18	prediction	T078	C0681842
28412023	22	32	activators	T121,T123	C0751968
28412023	41	46	human	T016	C0086418
28412023	47	79	constitutive androstane receptor	T116,T192	C0914906
28412023	86	95	structure	T085	C0026383
28412023	103	165	three-dimensional quantitative structure-activity relationship	T081	C0887820
28412023	166	173	methods	T170	C0025663
28412023	178	210	constitutive androstane receptor	T116,T192	C0914906
28412023	212	215	CAR	T116,T192	C0914906
28412023	217	223	NR1I3)	T116,T192	C0663285
28412023	224	248	regulates the expression	T045	C2755857
28412023	252	260	numerous	T081	C0439064
28412023	261	278	drug-metabolizing	T044	C0683140
28412023	279	286	enzymes	T116,T126	C0014442
28412023	291	303	transporters	T116,T123	C0007292
28412023	309	321	upregulation	T044	C0041904
28412023	333	340	enzymes	T116,T126	C0014442
28412023	352	358	CYP2B6	T116,T126	C0534137
28412023	363	366	CAR	T116,T192	C0914906
28412023	367	377	activators	T121,T123	C0751968
28412023	422	428	severe	T080	C0205082
28412023	429	451	drug-drug interactions	T044	C0687133
28412023	453	457	DDIs	T044	C0687133
28412023	482	491	effective	T080	C1704419
28412023	492	516	computational approaches	T062	C1516769
28412023	533	536	CAR	T116,T192	C0914906
28412023	590	652	three-dimensional quantitative structure-activity relationship	T081	C0887820
28412023	654	661	3D-QSAR	T081	C0887820
28412023	663	669	models	T170	C3161035
28412023	685	688	CAR	T116,T192	C0914906
28412023	689	699	activating	T043	C1514758
28412023	700	707	potency	T080	C3245505
28412023	711	720	compounds	T121	C1254351
28412023	737	751	drug-discovery	T062	C0920472
28412023	752	759	process	T067	C1522240
28412023	761	767	Models	T170	C3161035
28412023	791	827	comparative molecular field analysis	T063	C1513380
28412023	829	834	CoMFA	T063	C1513380
28412023	849	858	molecular	T167	C0567416
28412023	859	869	alignments	T081	C1706765
28412023	873	888	ligands binding	T044	C1517880
28412023	892	895	CAR	T116,T192	C0914906
28412023	931	945	ligand-docking	T044	C1522290
28412023	952	964	28 compounds	T121	C1254351
28412023	988	993	CoMFA	T063	C1513380
28412023	994	999	model	T170	C3161035
28412023	1001	1012	modified by	T080	C0205349
28412023	1022	1032	lipophilic	T081	C0598631
28412023	1033	1042	parameter	T081	C0598631
28412023	1112	1130	predictive ability	T080	C1514307
28412023	1191	1205	predictability	T081	C0237793
28412023	1213	1220	3D-QSAR	T081	C0887820
28412023	1221	1226	model	T170	C3161035
28412023	1231	1234	CAR	T116,T192	C0914906
28412023	1235	1245	activation	T043	C1514758
28412023	1276	1285	compounds	T121	C1254351
28412023	1304	1323	external validation	T062	C1519941
28412023	1343	1350	results	T169	C1274040
28412023	1369	1376	3D-QSAR	T081	C0887820
28412023	1377	1382	model	T170	C3161035
28412023	1416	1423	precise	T080	C2828393
28412023	1424	1434	prediction	T078	C0681842
28412023	1438	1441	CAR	T116,T192	C0914906
28412023	1442	1452	activating	T043	C1514758
28412023	1453	1460	potency	T080	C3245505
28412023	1503	1518	drug candidates	T121	C1254351
28412023	1524	1533	minimized	T080	C1524031
28412023	1534	1537	DDI	T044	C0687133
28412023	1538	1542	risk	T078	C0035647
28412023	1554	1570	enzyme-induction	T045	C0014431
28412023	1578	1583	early	T079	C1279919
28412023	1584	1598	drug-discovery	T062	C0920472
28412023	1599	1604	stage	T079	C1306673